bs-20619R [Primary Antibody]
MMP9 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: MMP9

Immunogen Range: 601-700/730


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 4318

Swiss Prot: P14780

Source: KLH conjugated synthetic peptide derived from mouse MMP9

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly- -Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)

Predicted Molecular Weight: 81


Cross Reactive Species: Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Wang, Huihui. et al. Anti-inflammatory and Antioxidant Effects of Pyrroloquinoline Quinone in L-NAME-Induced Preeclampsia-Like Rat Model. 2021 Sep 2Read more>>
  • Ping Lin. et al. Integrated bioinformatics analysis of the anti-atherosclerotic mechanisms of the polysaccharide CM1 from Cordyceps militaris. Int J Biol Macromol. 2021 OcRead more>>
  • Chengnan Tian. et al. CREB1 transcription-activated lncRNA PVT1 promotes cardiac fibrosis via miR-145/HCN1 axis. Int J Cardiol. 2022 JaRead more>>
  • Xu Huang. et al. Osteopontin-Targeted and PPAR-Agonist-Loaded Nanoparticles Efficiently Reduce Atherosclerosis in Apolipoprotein E/ Mice. ACS OMEGA. 2022;7(33):2876728778Read more>>
VALIDATION IMAGES

Lane 1: Recombinant MMP9-His protein probed with MMP9 Polyclonal Antibody, Unconjugated (bs-20619R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.